Alpha Profiles · Company Profile

BriaCell Therapeutics Corp.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/briacell-therapeutics-corp

Entity: Public listing published
Primary listing: NASDAQ: BCTX
Verification: Partially verified
Last reviewed: 2026-10-04T04:48:06.915082+00:00

Overview

Alpha's canonical identity and public leadership record for BriaCell Therapeutics Corp..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

4 public records

Gadi Levin, CA, MBA

Chief Financial Officer and Corporate Secretary

State: confirmed
Effective: From Oct 16, 2025
Confidence: 94%
Evidence: BCTXZ 10-K executive officersOct 16, 2025

Giuseppe Del Priore, MD, MPH

Chief Medical Officer

State: confirmed
Effective: From Oct 16, 2025
Confidence: 94%
Evidence: BCTXL 10-K executive officersOct 16, 2025

Miguel A. Lopez-Lago, PhD

Chief Scientific Officer

State: confirmed
Effective: From Oct 16, 2025
Confidence: 94%
Evidence: BCTXZ 10-K executive officersOct 16, 2025

William V. Williams, MD, FRCP

President, Chief Executive Officer, and Director

State: confirmed
Effective: From Oct 16, 2025
Confidence: 94%
Evidence: BCTXL 10-K executive officersOct 16, 2025

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 4, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

1 public record

Martin E. Schmieg

Director

IndependentAuditCompensation · Chair

State: confirmed
Effective: From Jan 1, 2020
Confidence: 85%
Evidence: BriaCell Therapeutics Corp. DEF 14A 2026-02-12Feb 12, 2026

Committees

3 public records

Membership and chair roles are projected from current board seats. A chair is shown only when a stored chair flag says so.

Audit

Chair: Dr. Vaughn C. Embro-Pantalony
Members: Dr. Vaughn C. Embro-Pantalony (Chair); Dr. Jane Gross; Martin E. Schmieg

Compensation

Chair: Martin E. Schmieg
Members: Martin E. Schmieg (Chair); Dr. Vaughn C. Embro-Pantalony

Nominating and Governance

Chair: Mr. Jamieson Bondarenko
Members: Mr. Jamieson Bondarenko (Chair); Dr. Rebecca Taub

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-10-04T04:48:06.915082+00:00